In skinned myocardium, cAMP-dependent protein kinase (PKA)-catalyzed phosphorylation of cardiac myosin binding protein-C (cMyBP-C) and troponin I (cTnI) leads to a decrease in myofilament Ca2+-sensitivity and an acceleration in the kinetics of cross-bridge cycling. To examine the relative roles of cTnI and cMyBP-C phosphorylation in altering contractile function, we determined the Ca2+-sensitivity of force (pCa50) and the rate of force redevelopment (ktr) in untreated and PKA-treated murine myocardium expressing: (1) phosphorylatable cTnI and cMyBP-C (WT), (2) non-phosphorylatable cTnI with serines23/24/43/45 and threonine144 residues mutated to alanines (cTnIala5), (3) phosphorylatable cTnI on a cMyBP-C null background (cMyBP-C-/-), and (4) non-phosphorylatable cTnI on a cMyBP-C null background (cTnIala5/cMyBP-C-/-). A novel aspect of this study was the use of 2,3-Butandione Monoxime (BDM) treatments to reduce the basal levels of myosin regulatory light chain (RLC) phosphorylation to near zero in order to more accurately define the functional consequences of removing cMyBP-C and/or cTnI phoshorylation in transgenic myocardium. Our results showed that in the absence of RLC phosphorylation, PKA-treatment decreased pCa50 in WT, cTnIala5, and cMyBP-C-/- myocardium by 0.13, 0.08 and 0.09 pCa units, respectively, but had no effect in cTnIala5/cMyBP-C-/- myocardium. In WT and cTnIala5 myocardium, PKA treatment increased ktr at submaximal levels of activation; however, treatment did not have an effect on ktr in cMyBP-C-/- and cTnIala5/cMyBP-C-/- myocardium. Together, these results indicate that the attenuation of the myofilament force response following PKA treatment is due to phosphorylation of both cTnI and cMyBP-C and that the reduced Ca2+-sensitivity of force mediated by phosphorylation of cMyBP-C is most likely due to an increased rate constant of cross-bridge detachment that also contributes to an acceleration of cross-bridge cycling kinetics.